MicroPort’s Endovastec Unit Delivers Strong Q1 2026 Earnings Lift

MicroPort Scientific ( (HK:0853) ) just unveiled an update.

Shanghai MicroPort Endovascular MedTech, the 40.32%-owned endovascular unit of MicroPort Scientific, reported double-digit growth for the first quarter of 2026, underscoring resilient demand for its vascular intervention products. Revenue for the three months to 31 March 2026 rose 11.45% year on year to RMB370.2 million, while profit advanced 19.16% to RMB179.8 million, and net profit attributable to equity owners climbed 19.44% to RMB154.8 million.

Endovastec’s balance sheet also strengthened modestly, with total assets up 3.29% since year-end to RMB4.79 billion and equity attributable to shareholders improving 3.50% to RMB4.22 billion, suggesting continued capital accumulation to support future growth. As these unaudited figures are prepared under PRC accounting standards and reflect only Endovastec, MicroPort reminded investors that the data do not represent the group’s overall performance and urged caution when dealing in its securities.

The most recent analyst rating on (HK:0853) stock is a Hold with a HK$8.81 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.

More about MicroPort Scientific

MicroPort Scientific Corporation is a China-based medical device company with a diversified portfolio spanning cardiovascular, endovascular, orthopaedic and other interventional products. Through its 40.32%-owned subsidiary Shanghai MicroPort Endovascular MedTech (Endovastec), listed on Shanghai’s STAR Market, the group targets the fast-growing market for endovascular therapies in China and abroad.

Average Trading Volume: 13,629,033

Technical Sentiment Signal: Sell

Current Market Cap: HK$16.91B

For an in-depth examination of 0853 stock, go to TipRanks’ Overview page.